Baxter (NYSE:BAX) announced today that it received FDA clearance for its Homechoice Claria automated peritoneal dialysis (APD) system with Sharesource.
Homechoice Claria is designed to combine its simple user interface with the Sharesource two-way remote patient management platform for patients on peritoneal dialysis, according to a news release. The system is cleared for both adult and pediatric populations.
Deerfield, Ill.-based Baxter said Sharesource offers a way for patients and clinicians to stay connected and proactively address key aspects of PD therapy with accurate daily treatment data and analytics for remote management, keeping patients safe at home.
Combined with Homechoice Claria, clinicians then have greater visibility to patient adherence patterns to allow for early intervention and increased focus on proactive care. The system also includes intuitive control buttons and an easy-to-read screen, along with the MyClaria app for step-by-step, voice-activated instructions to guide patients through therapy.
According to Baxter, Homechoice Claria with Sharesource will be made available in the U.S. in the coming weeks.
“Our goal remains to expand accessibility to home-based therapy for U.S. patients with kidney failure,” Baxter U.S. renal care GM Gavin Campbell said in the release. “Homechoice Claria with Sharesource will support accelerated home dialysis growth by bringing the benefits of a two-way connected automated peritoneal dialysis system combined with a simple, intuitive device to more patients in the U.S.”
